607
Views
9
CrossRef citations to date
0
Altmetric
Articles; Medical Biotechnology

Evaluation of prognostic utility of MIB-1 and p53 expression in pituitary adenomas: correlations with clinical behaviour and follow-up results

, , , , , , , & show all
Pages 502-507 | Received 25 Nov 2013, Accepted 31 Jan 2014, Published online: 22 Aug 2014

References

  • Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev. 1998;19:798–827.
  • Hsu DW, Hakim F, Biller BM, de la Monte S, Zervas NT, Klibanski A, Hedley-Whyte ET. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg. 1993;78:753–761.
  • Landolt AM, Shibata T, Kleihues P. Growth rate of human pituitary adenomas. J Neurosurg. 1987;67:803–806.
  • Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991;138:867–873.
  • DeLellis R. Pathology and genetics of tumours of endocrine organs: WHO classification of tumours. Lyon: IARC Press; 2004.
  • Schreiber S, Saeger W, Ludecke DK. Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary. 1999;1:213–220.
  • Gejman R, Swearingen B, Hedley-Whyte ET. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol. 2008;39:758–766.
  • Hentschel SJ, McCutcheon E, Moore W, Durity FA. p53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci. 2003;30:215–219.
  • Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumour growth fractions. Neurosurgery. 1996;38:765–770.
  • Kitz K, Knosp E, Koos WT, Korn A. Proliferation in pituitary adenomas: measurement by MAb KI 67. Acta Neurochir Suppl (Wien). 1991;53:60–64.
  • Knosp E, Kitz K, Perneczky A. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery. 1989;25:927–930.
  • Zhao D, Tomono Y, Nose T. Expression of P27kip 1 and Ki-67 in pituitary adenomas: an investigation of marker of adenoma invasiveness. Acta Neurochir (Wien). 1999;141:187–192.
  • Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G. Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol. 1999;52:107–111.
  • Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, Riehle DL, Laws ER Jr. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 2006;59:341–353.
  • Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38:99–106.
  • Yonezawa K, Tamaki N, Kokunai T. Clinical features and growth fractions of pituitary adenomas. Surg Neurol. 1997;48:494–500.
  • Mastronardi L, Guiducci A, Puzzilli F, Maira G. Anterior pituitary adenomas in patients aged more than 65 years: analysis of growth fraction (using the MIB-1 monoclonal antibody) and of clinical features in comparison to younger patients. Clin Neurol Neurosurg. 2002;104:44–48.
  • Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005;90:3089–3099.
  • Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997;82:2102–2107.
  • Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumour volume doubling time, patient age, and MIB-1 index. J Neurosurg. 2003;98:359–365.
  • Mastronardi L, Guiducci A, Puzzilli F. Lack of correlation between Ki-67 labelling index and tumour size of anterior pituitary adenomas. BMC Cancer. 2001;1:12.
  • Chacko G, Chacko AG, Kovacs K, Scheithauer BW, Scheithauer BW, Mani S, Muliyil JP, Seshadri MS. The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary. 2010;13:337–344.
  • Prevedello DM, Jagannathan J, Jane JA Jr, Lopes MB, Laws ER Jr. Relevance of high Ki-67 in pituitary adenomas. Case report and review of the literature. Neurosurg Focus. 2005;19(5):E11.
  • Abe T, Sanno N, Osamura YR, Matsumoto K. Proliferative potential in pituitary adenomas: measurement by monoclonal antibody MIB-1. Acta Neurochir (Wien). 1997;139(7):613–618.